How the Ozempic Injection Works for Weight Loss — and What UK Patients Should Know

You've heard about Ozempic for weight loss, here's the situation you're actually in

Perhaps a friend mentioned it, or you saw something online. You searched for Ozempic, found dramatic before-and-after accounts, and now you're trying to work out whether it's obtainable in the UK for weight management. The honest answer is: not under that brand name, not lawfully, and not for this purpose. Ozempic is semaglutide, and semaglutide absolutely does produce meaningful weight loss, that part isn't myth. The complication is purely one of licensing.

In the UK, Eli Lilly and Novo Nordisk medicines carry separate licences for different conditions. Novo Nordisk's Ozempic pen (0.5 mg and 1 mg doses) is authorised by the MHRA specifically for blood-sugar control in adults with type 2 diabetes. Prescribing it for weight loss in someone without diabetes would be off-label use. The same molecule, reformulated and studied at a higher 2.4 mg maintenance dose, was approved under the brand name Wegovy for weight management, a distinction the NHS semaglutide medicines page sets out plainly. So if weight loss is your goal and you don't have a diabetes diagnosis, Wegovy is the relevant licensed option to explore with a prescriber. Our overview of Ozempic and weight loss in the UK goes into the background of how this confusion developed.

That's worth sitting with for a moment, because it changes which questions you should be asking.

What the semaglutide injection actually does inside your body

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. Its job is to tell the brain you've had enough, prompt the pancreas to release insulin, and slow the rate at which food leaves your stomach. In people living with obesity, this signalling system often operates at a lower level than it should. Semaglutide is a synthetic version of GLP-1 that binds to the same receptors but resists the enzyme that normally breaks natural GLP-1 down within minutes. A single weekly injection sustains that signal across the whole week.

The practical result is that appetite falls noticeably, not through willpower, but through a shift in the body's hunger chemistry. Food moves through the stomach more slowly, so fullness arrives sooner and lasts longer. Over months, people eat less without the gnawing hunger that typically defeats calorie-restricted diets. The STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults with obesity and found that semaglutide 2.4 mg produced an average weight reduction of around 15% over 68 weeks alongside lifestyle support, a result that placed it well ahead of any previously approved weight-management medicine at the time.

The injection itself goes under the skin, typically the abdomen, thigh, or upper arm. For practical detail on technique and site rotation, our page on where to inject semaglutide covers the specifics. Dosing starts low to let the body adjust, then increases in stages under prescriber guidance, a schedule our page on injection frequency explains.

Side effects worth knowing about before you decide anything

Because semaglutide slows gastric emptying, the most common side effects are gastrointestinal. Nausea is the one people notice most, particularly in the first few weeks or after a dose increase. Loose stools, constipation, reflux, and burping are also reported. For most people these settle as the body adapts; the graduated dose schedule exists largely to reduce their intensity. Fatigue and mild headache appear in some people, especially early on.

More serious effects are less common but real. In January 2026 the MHRA issued a Drug Safety Update drawing attention to acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines: severe, persistent stomach pain that radiates to the back (with or without vomiting) needs prompt medical attention, not a wait-and-see approach. Anyone on semaglutide should also tell their surgical team before any planned procedure, as delayed gastric emptying affects anaesthesia risk. You can report any suspected side effect through the MHRA Yellow Card scheme, which is open to patients as well as clinicians.

These medicines are not recommended during pregnancy, while breastfeeding, or when trying to conceive, and they are not licensed for anyone under 18. A prescriber will go through contraindications in detail before any treatment begins.

What IS available for weight loss in the UK, and how to access it properly

Two injectable GLP-1 medicines carry UK weight-management licences: Wegovy (semaglutide 2.4 mg, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly), the latter being a dual GIP and GLP-1 receptor agonist, the only one of its kind currently licensed here. Our weight-loss treatment overview compares both at a practical level. If you're curious about the cost of these treatments, our Wegovy price comparison page sets out what private treatment typically costs and what a legitimate price should include.

On the NHS, access to both medicines is currently phased and criteria-based, waiting lists for specialist services can be long. Private treatment through a GPhC-registered pharmacy is the route most people use when they don't meet the current NHS thresholds or don't want to wait. A question our prescribers hear most weeks is whether there's a shortcut: there isn't one that's safe. These are prescription-only medicines. Legitimate access always starts with a clinical consultation, a real prescriber reading your answers and your health history, not a checkbox form auto-approving an order before the school run. Our clinical team reviews every consultation personally. If you'd like to know how many injections a course typically involves before results become noticeable, our page on how many injections are needed addresses that directly. And if you have further questions before taking any steps, our FAQs cover the most common ones. When you're ready to explore whether treatment is appropriate for you, you can start a free consultation with our prescribing team.